Corrigendum to "A case-control study to identify molecular risk factors for local recurrence in young breast cancer patients" [Radiother Oncol 156 (2021) 127-135]

The authors regret that in the above-mentioned article the acknowledgements section was not complete. Important contributors were missing from the list. The acknowledgements in full are below, and have been amended online. Furthermore, the affiliation of Femke van der Leij changed from the Netherlands Cancer Institute to UMC Utrecht. Also, we acknowledge and thank Alain Fourquet, project leader in France, for coordinating the Young Boost Trial in France and the following investigators for their active participation: L. Scheijmans, Tilburg (NL), A.H. Westenberg, Arnhem (NL), D. Schinagl, Nijmegen (NL), M. van Hezewijk, Leiden (NL); M.J.C. van der Sangen Eindhoven (NL); M.C. Stenfert Kroese, Deventer (NL); J.J.Jobsen, Enschede (NL); J.M. Immink, Delft (NL); M.E. Mast, Den Haag (NL); F.M. Gescher, Den Haag (NL); N. Bijker, Amsterdam (NL); J.W.M. Mens, Rotterdam (NL); W.G.J.M. Smit, Leeuwarden (NL); D.H.F. Rietveld, éAmsterdam (NL); J.H. Maduro, UMCG, Groningen (NL); C. Lemansky, Montpellier (Fr), I. Lecouillard, Rennes (Fr); C Breton-Callu, Bordeaux (Fr); H. Marsiglia, Villejuif (Fr); J. Thariat, Nice (Fr); A. Benyoucef, Rouen (Fr); A. Labib, Saint Cloud (Fr); M. Aumont, Saint Herblain (Fr); P. Bontemps, Besancon (Fr); C. Le Foll, Lagny (Fr); Y. Belkacemi, Créteil (Fr); O. Chapet, Lyon (Fr); V. Strnad, Erlangen (De). A case-control study to identify molecular risk factors for local recurrence in young breast cancer patientsRadiotherapy and OncologyVol. 156PreviewBreast conserving therapy (BCT), consisting of breast conserving surgery followed by whole breast irradiation is the standard treatment for early stage breast cancer. In the EORTC boost-no boost trial a boost of 16 Gy to the primary tumor bed reduced the LR rate from 10.2 to 6.2% (p < 0.01) [1]. Age and boost were the only factors independently related to local control [2]. As younger patients have a higher LR risk compared to older women, the boost dose reduces the LR risk with the largest absolute benefit in young patients. Full-Text PDF